platinum has been researched along with Adenocarcinoma of Lung in 32 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 20 (62.50) | 24.3611 |
| 2020's | 12 (37.50) | 2.80 |
| Authors | Studies |
|---|---|
| Hara, S; Hata, A; Komatsu, M; Ninomaru, T | 1 |
| Chen, Z; Ke, Y; Lin, Z; Lu, Z; Rao, D; Sun, T; Wu, S; Ye, M; Zhang, D; Zhang, X | 1 |
| Du, LQ; Huang, Y; Liang, CJ; Liang, H; Qin, QP; Yang, Y | 1 |
| Bleckmann, A; Frost, N; Griesinger, F; Grohé, C; Janning, M; Kollmeier, J; Reck, M; Reinmuth, N; Sebastian, M; Thomas, M | 1 |
| Baak, JPA; Feng, J; Guo, H; Huang, X; Li, H; Zhu, L | 1 |
| Edwards, A; Falk, S; Hackshaw, A; Hatton, M; Jones, R; Lal, R; Lee, SM; Lewanski, C; Ngai, Y; Rudd, R; Skailes, G; Toy, E; Upadhyay, S; Woll, PJ | 1 |
| Hamburger, T; Kadouri, L; Lipson, D; Nechushtan, H; Peretz, T; Rottenberg, Y; Zick, A | 1 |
| Chen, C; Chen, T; Fu, S; He, LN; Hong, S; Li, H; Lin, Z; Wang, Y; Zhang, L; Zhang, X; Zhou, Y | 1 |
| Han, X; Han, Y; He, X; Huang, Y; Pi, J; Shi, Y; Song, Y; Tan, Q; Wu, D; Yang, J; Yang, S; Yao, J; Zhang, Z; Zhou, S; Zuo, L | 1 |
| Arriola, E; Bellosillo, B; Carcereny, E; Chaib, I; Clavé, S; Dalmases, A; Gibert, J; Hardy-Werbin, M; Longarón, R; Morán, T; Piquer, G; Rocha, P; Salido, M; Taus, Á | 1 |
| Bradford, DS; Crane, J; Deal, AM; Irvin, W; Lee, C; Morgensztern, D; Muss, HB; Pecot, C; Pennell, N; Socinski, M; Stevenson, JP; Stinchcombe, T; Villaruz, LC; Weiss, JM; West, HJ | 1 |
| Bierbach, U; Ding, S; Hackett, CL; Hackett, RG; Liu, F | 1 |
| Gurunathan, S; Jeyaraj, M; Kang, MH; Kim, JH | 1 |
| Hao, X; Li, J; Lin, L; Xing, P; Xu, Z | 1 |
| Pathak, R; Salgia, R | 1 |
| Chang, GR; Chen, CM; Chen, W; Chong, KY; Cidem, A; Lin, CH; Staniczek, T; Tsai, YT; Wang, JL; Yen, CC | 1 |
| Li, J; Liu, Y; Wang, Z; Yang, L; Zhai, X; Zheng, Q; Zhu, Y | 1 |
| Gao, H; He, K; Li, L; Li, X; Liu, X; Qin, H; Qu, L; Tang, C; Wang, L; Wang, W; Xu, B; Yang, L | 1 |
| Ren, X; Wang, J; Wei, F; Xiong, Y; Zhao, N; Zheng, Y | 1 |
| Kasahara, K; Sone, T; Tambo, Y | 1 |
| Gong, P; Ma, D; Ma, X; Wang, Y; Wei, Y | 1 |
| Alamgeer, M; Barrow, R; Boolell, V; Burgess, A; Cain, JE; Chin, V; Croucher, DR; de Kretser, DM; Ganju, V; Gonzalez-Rajal, A; Han, JZR; Harrison, CA; Hastings, JF; Hedger, MP; Jayasekara, WSN; Kita, B; Kostyrko, K; Kumar, B; Lee, HC; Lorensuhewa, N; Marini, KD; Marquez, C; Martelotto, LG; McCloy, RA; Oakes, SR; Robinson, BW; Rossello, FJ; Sweet-Cordero, EA; Szczepny, A; Vaghjiani, V; Watkins, DN; Waugh, T; Wu, J | 1 |
| Li, B; Li, P; Li, X; Shen, S; Shi, Y; Zhang, F | 1 |
| Germonpré, P; Van den Wyngaert, T | 1 |
| Isaka, T; Ito, H; Katayama, K; Masuda, M; Nakayama, H; Yamada, K; Yokose, T | 1 |
| Hao, X; He, P; Hu, X; Li, J; Shi, Y; Wang, B; Wang, H; Wang, Y; Wang, Z; Yang, S; Yu, S; Zhang, X | 1 |
| Bierbach, U; Ding, S; Kucera, GL; Pickard, AJ | 1 |
| Gan, B; Huang, Y; Liao, R; Lou, N; Wu, Y; Xu, C; Yan, H; Yang, J; Yang, X; Yang, Y; Zhou, Q | 1 |
| Fang, C; Fu, Z; Jiang, H; Li, J; Lu, Q; Pei, Z; Wang, E; Wang, H; Wang, J; Wang, S | 1 |
| Chen, YM; Lee, YC; Lin, YH; Perng, RP; Tseng, YC; Tseng, YH; Whang-Peng, J | 1 |
| Huo, Z; Jiang, SY; Wang, MZ; Xu, Y; Zhang, J; Zhao, J; Zhong, W | 1 |
| Ding, X; Fei, K; Liu, D; Lu, Y; Su, B; Xu, W; Yang, Y | 1 |
1 review(s) available for platinum and Adenocarcinoma of Lung
| Article | Year |
|---|---|
Small-Cell Lung Cancer Transformation in Patients With Pulmonary Adenocarcinoma: A Case Report and Review of Literature.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Fatal Outcome; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Pemetrexed; Platinum; Quinazolines; Small Cell Lung Carcinoma | 2016 |
6 trial(s) available for platinum and Adenocarcinoma of Lung
| Article | Year |
|---|---|
Rationale and Design of the Phase II ANTELOPE Study of Atezolizumab, Carboplatin and nab-Paclitaxel vs. Pembrolizumab, Platinum and Pemetrexed in TTF-1 Negative, Metastatic Lung Adenocarcinoma (AIO-TRK-0122).
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Pemetrexed; Platinum; Retrospective Studies; Thyroid Nuclear Factor 1 | 2023 |
The clinical role of VeriStrat testing in patients with advanced non-small cell lung cancer considered unfit for first-line platinum-based chemotherapy.
Topics: Adenocarcinoma of Lung; Aged; Aged, 80 and over; Biomarkers, Tumor; Blood Proteins; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Double-Blind Method; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Platinum; Predictive Value of Tests; Protein Kinase Inhibitors; Proteomics; Survival Rate | 2019 |
Nab-paclitaxel in older patients with non-small cell lung cancer who have developed disease progression after platinum-based doublet chemotherapy.
Topics: Adenocarcinoma of Lung; Aged; Aged, 80 and over; Albumins; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Paclitaxel; Platinum; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate | 2020 |
Second-line erlotinib after failure of pemetrexed-containing chemotherapy in advanced non-small cell lung cancer (NSCLC): Real-world effectiveness, safety and tolerability.
Topics: Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Pemetrexed; Platinum; Prognosis; Prospective Studies; Salvage Therapy; Survival Rate | 2019 |
[Efficacies of gefitinib versus paclitaxel/carboplatin for patients with advanced pulmonary adenocarcinoma].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Asian People; Carboplatin; Disease-Free Survival; Gefitinib; Hospitals, General; Humans; Lung Neoplasms; Paclitaxel; Platinum; Quinazolines; Smoking | 2014 |
Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitor Treatment and Salvage Chemotherapy in EGFR-Mutated Elderly Pulmonary Adenocarcinoma Patients.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Cisplatin; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Mutation; Pemetrexed; Platinum; Protein Kinase Inhibitors; Retrospective Studies; Salvage Therapy; Survival Analysis; Treatment Outcome | 2015 |
25 other study(ies) available for platinum and Adenocarcinoma of Lung
| Article | Year |
|---|---|
Heterogeneity or transformation? A whack-a-mole case of EGFR-mutant lung adenocarcinoma and small cell carcinoma: A case report.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Carcinoma, Small Cell; Drug Resistance, Neoplasm; ErbB Receptors; Etoposide; Humans; Lung Neoplasms; Mutation; Platinum; Protein Kinase Inhibitors; Small Cell Lung Carcinoma | 2022 |
Pembrolizumab for the better treatment of EGFR-mutant T790M-negative advanced lung adenocarcinoma patients than dual treatment of pemetrexed plus platinum after tyrosine kinase inhibitor treatment failure.
Topics: Adenocarcinoma of Lung; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Humans; Lung Neoplasms; Mutation; Pemetrexed; Platinum; Prospective Studies; Protein Kinase Inhibitors; Treatment Failure | 2022 |
Platinum(II) 5-substituted-8-hydroxyquinoline coordination compounds induces mitophagy-mediated apoptosis in A549/DDP cancer cells.
Topics: Adenocarcinoma of Lung; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cisplatin; Dimethyl Sulfoxide; Drug Resistance, Neoplasm; Humans; Mice; Mice, Nude; Mitophagy; Oxyquinoline; Platinum | 2023 |
In stage IV pulmonary adenocarcinoma patients, treatment with Traditional Chinese Medicine alone gives prognostically superior results to treatment with Platinum-Based Chemotherapy alone.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Drugs, Chinese Herbal; Humans; Lung Neoplasms; Medicine, Chinese Traditional; Platinum | 2023 |
Homologous recombination in lung cancer, germline and somatic mutations, clinical and phenotype characterization.
Topics: Adenocarcinoma of Lung; Aged; Biomarkers, Tumor; BRCA1 Protein; BRCA2 Protein; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Fanconi Anemia Complementation Group N Protein; Female; Follow-Up Studies; Germ-Line Mutation; Homologous Recombination; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Platinum; Prognosis; Retrospective Studies; Survival Rate | 2019 |
First-line platinum-based chemotherapy and survival outcomes in locally advanced or metastatic pulmonary lymphoepithelioma-like carcinoma.
Topics: Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Platinum; Prognosis; Retrospective Studies; Survival Rate; Taxoids | 2019 |
Tracking longitudinal genetic changes of circulating tumor DNA (ctDNA) in advanced Lung adenocarcinoma treated with chemotherapy.
Topics: Adenocarcinoma of Lung; Adult; Aged; Circulating Tumor DNA; Cohort Studies; Female; Gene Silencing; Humans; Longitudinal Studies; Lung Neoplasms; Male; Middle Aged; Mutation; Platinum; Polymorphism, Single Nucleotide; Prognosis; Smoking | 2019 |
Concomitant genomic alterations in KRAS mutant advanced lung adenocarcinoma.
Topics: Adenocarcinoma of Lung; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Follow-Up Studies; Genomics; High-Throughput Nucleotide Sequencing; Humans; Lung Neoplasms; Mutation; Platinum; Prognosis; Proto-Oncogene Proteins p21(ras); Survival Rate | 2020 |
Evaluation of a Platinum-Acridine Anticancer Agent and Its Liposomal Formulation in an in vivo Model of Lung Adenocarcinoma.
Topics: A549 Cells; Acridines; Adenocarcinoma of Lung; Animals; Antineoplastic Agents; Cell Proliferation; Drug Compounding; Drug Screening Assays, Antitumor; Female; Humans; Liposomes; Lung Neoplasms; Mice; Mice, Nude; Models, Biological; Molecular Structure; Neoplasms, Experimental; Organoplatinum Compounds; Platinum | 2021 |
Platinum Nanoparticles Enhance Exosome Release in Human Lung Epithelial Adenocarcinoma Cancer Cells (A549): Oxidative Stress and the Ceramide Pathway are Key Players.
Topics: A549 Cells; Acetylcholinesterase; Acetylcysteine; Adenocarcinoma of Lung; Aniline Compounds; Benzylidene Compounds; Cell Proliferation; Cell Survival; Ceramides; Enzyme Activation; Exosomes; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Lutein; Metal Nanoparticles; Neoplasm Proteins; Oxidative Stress; Particle Size; Platinum; RNA, Messenger; Serum; Sphingomyelin Phosphodiesterase; Static Electricity | 2021 |
Concurrent chemotherapy and first-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) with or without an antiangiogenic agent as first-line treatment in advanced lung adenocarcinoma harboring an EGFR mutation.
Topics: Adenocarcinoma of Lung; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Drug Therapy, Combination; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Platinum; Protein Kinase Inhibitors; Retrospective Studies | 2021 |
Near-Complete Response to Combined Pembrolizumab and Platinum-Doublet in a Patient With STK11/KRAS Mutated Advanced Lung Adenocarcinoma.
Topics: Adenocarcinoma of Lung; Antibodies, Monoclonal, Humanized; Biomarkers, Tumor; Humans; Lung Neoplasms; Male; Mutation; Neoplasm Staging; Platinum; Proto-Oncogene Proteins p21(ras); Treatment Outcome | 2022 |
Benefits of Metformin Combined with Pemetrexed-Based Platinum Doublets as a First-Line Therapy for Advanced Lung Adenocarcinoma Patients with Diabetes.
Topics: Adenocarcinoma of Lung; Aged; Antineoplastic Combined Chemotherapy Protocols; Diabetes Complications; Diabetes Mellitus; Disease-Free Survival; Drug Therapy, Combination; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Metformin; Middle Aged; Mutation; Pemetrexed; Platinum; Probability; Proportional Hazards Models; Retrospective Studies; Taiwan; Treatment Outcome | 2021 |
Impact of platinum/pemetrexed combination versus other platinum-based regimens on adjuvant chemotherapy in resected lung adenocarcinoma.
Topics: Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Leukopenia; Male; Middle Aged; Neutropenia; Pemetrexed; Platinum; Retrospective Studies; Taxoids | 2017 |
Mass spectrometry-based serum peptidome profiling accurately and reliably predicts outcomes of pemetrexed plus platinum chemotherapy in patients with advanced lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Carboplatin; Disease-Free Survival; Female; Humans; Lung Neoplasms; Male; Mass Spectrometry; Middle Aged; Pemetrexed; Peptides; Platinum; Retrospective Studies; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2017 |
Prognostic value of pretreatment inflammatory biomarkers in advanced lung adenocarcinoma patients receiving first-line pemetrexed/platinum doublet.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Disease-Free Survival; Female; Humans; Inflammation; Lung Neoplasms; Lymphocytes; Male; Middle Aged; Monocytes; Neutrophils; Pemetrexed; Platelet Count; Platinum; Prognosis | 2017 |
Combination Treatment Using an EGFR Tyrosine Kinase Inhibitor plus Platinum-Based Chemotherapy for a Patient with Transformed Small Cell Carcinoma and EGFR-Mutated Lung Adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; ErbB Receptors; Female; Humans; Lung Neoplasms; Middle Aged; Platinum; Protein Kinase Inhibitors | 2017 |
Effect of platinum-based chemotherapy on EGFR gene mutation status in lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Agents; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Platinum; Treatment Outcome | 2018 |
Inhibition of activin signaling in lung adenocarcinoma increases the therapeutic index of platinum chemotherapy.
Topics: A549 Cells; Activins; Adenocarcinoma of Lung; Animals; Carboplatin; Cell Line, Tumor; Cell Survival; Follistatin; Humans; Lung Neoplasms; Male; Mice; Platinum; Signal Transduction; Xenograft Model Antitumor Assays | 2018 |
[Association between the HER2 Gene Status and the Efficacy of First-line Pemetrexed Combined with Platinum Chemotherapy in Patients with Advanced Lung
Adenocarcinoma].
Topics: Adenocarcinoma of Lung; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Genes, erbB-2; Humans; Male; Middle Aged; Mutation; Pemetrexed; Platinum; Retrospective Studies; Treatment Outcome | 2019 |
Efficacy of Platinum-Based Adjuvant Chemotherapy on Prognosis of Pathological Stage II/III Lung Adenocarcinoma based on EGFR Mutation Status: A Propensity Score Matching Analysis.
Topics: Adenocarcinoma of Lung; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuvant; ErbB Receptors; Exons; Female; Humans; Male; Mutation; Neoplasm Grading; Neoplasm Staging; Platinum; Propensity Score; Safety Management | 2019 |
[Efficacy of chemotherapy after EGFR-TKIs resistance in 191 patients with Unknow EGFR gene mutation in advanced lung adenocarcinoma].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; ErbB Receptors; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Pemetrexed; Platinum; Protein Kinase Inhibitors; Retrospective Studies; Survival Rate | 2013 |
Design of enzymatically cleavable prodrugs of a potent platinum-containing anticancer agent.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Cell Line, Tumor; Drug Design; Humans; Hydrolysis; Lung Neoplasms; Platinum; Prodrugs; Valproic Acid | 2014 |
Expression of ERCC1, TYMS, RRM1, TUBB3, non-muscle myosin II, myoglobin and MyoD1 in lung adenocarcinoma pleural effusions predicts survival in patients receiving platinum-based chemotherapy.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; DNA-Binding Proteins; Drug Resistance, Neoplasm; Endonucleases; Female; Gene Expression; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; MyoD Protein; Myoglobin; Myosin Type II; Platinum; Pleural Effusion, Malignant; Prognosis; Ribonucleoside Diphosphate Reductase; Thymidylate Synthase; Tubulin; Tumor Suppressor Proteins | 2015 |
Caspase 8 polymorphisms contribute to the prognosis of advanced lung adenocarcinoma patients after platinum-based chemotherapy.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Caspase 8; China; Disease-Free Survival; Female; Genotype; Haplotypes; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Platinum; Polymorphism, Single Nucleotide; Prognosis; Quality of Life | 2017 |